Drug
Shr6390
Shr6390: highest development phase Phase 3, developed by Jiangsu Hengrui Medicine. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| SHR6390 NCT03927456 | Phase 3 | Advanced Breast Cancer |
| SHR6390 tablet NCT04423601 | Phase 1 | Healthy Subjects |
Latest
No recent events.
Follow Shr6390 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.